Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 

-
...TBI increases risk of dementia by as much as two-fold
  



ALSP Inc. is led by a dedicated team of experienced executives, scientists and thought leaders that have extensive business and clinical experience in drug development.
Board of Directors

In addition to Michael Pierschbacher and Gregory Hook, the following individuals also serve on the Board of Directors of ALSP Inc.
J. Gregory Swendsen

President of Swendsen & Company

J. Gregory Swendsen is President of Swendsen & Company, a management company founded in 1984 that specializes in venture capital in the applied technologies. Mr. Swendsen is a founder of SuperGen, Inc. (NASDAQ: SUPG), a leading developer of anti-cancer drugs, a founder of Quark Biotech, and served on the board of AMUR Pharmaceuticals, which he financed prior to its sale to SuperGen. Mr. Swendsen has raised over $250 million for pharmaceutical and biotech companies. He currently sits on the board of Planet Biotech, and KineMed, Inc.
J. Gregory Swendsen

President of Swendsen & Company

J. Gregory Swendsen
President of Swendsen & Company


President of Swendsen & Company

President of Swendsen & Company

President of Swendsen & Company

President of Swendsen & Company
J. Gregory Swendsen is President of Swendsen & Company, a financial management company founded in 1984 that specializes in seed and venture capital in the life sciences and applied technologies. Mr. Swendsen is a founder of SuperGen, Inc. a leading developer of anti-cancer drugs, a founder of Quark Pharmaceuticals, Inc., which was acquired by SBI Biotech in 2012, and served on the board of AMUR Pharmaceuticals prior to its sale to SuperGen. In July 2011 SuperGen acquired Astex Pharmaceuticals, Inc. In October 2013 Astex was acquired by Otsuko Holdings Co. for $886 million. Mr. Swendsen currently sits on the board of American Life Science Pharmaceuticals, Inc., a clinical stage Alzheimer's and neurodegenerative disease company, and was an early investor in NovaBay Pharmaceuticals, Inc. (NYSE: NBY). He has raised over $500 million for pharmaceutical and biotech companies. 


Bernice R. Welles
Chief Executive Officer, Alquest Therapeutics, Inc. and Chief Medical Officer, Enject, Inc.

Bernice Welles has been Chief Executive Officer at Alquest Therapeutics, Inc. a neurodegenerative drug development company, since June, 2010, and Chief Medical Officer at Enject, Inc., a medical device company, since August 2009.  Prior to that she was Vice President, Development at Diobex, Inc., a venture-backed biotechnology company, for four years.  Dr. Welles has venture capital experience having been Venture Partner at MPM Capital, L.P. for four years and extensive pharmaceutical experience having been Vice President, Product Development and Senior Director and Director, Specialty Therapeutics Unit, Medical Affairs and Clinical Scientist, Medical Affairs at Genentech, Inc. for eight years.
nc. a neurodegenerative drug development company, since June, 2010, and Chief Medical Officer at Enject, Inc., a medical device company, since August 2009.  Prior to that she was Vice President, Development at Diobex, Inc., a venture-backed biotechnology company, for four years.  Dr. Welles has venture capital experience having been Venture Partner at MPM Capital, L.P. for four years and extensive pharmaceutical experience having been Vice President, Product Development and Senior Director and Director, Specialty Therapeutics Unit, Medical Affairs and Clinical Scientist, Medical Affairs at Genentech, Inc. for eight years.

Dr. Welles has a BA in Music from Brandeis University, a MS in Urban and Environmental Policy from Tufts University, a MD from Albany Medical College, and a M.B.A. from The Warton School of Business, University of Pennsylvania.  She has Medical Licensure, State of California, Diplomate, American Board of Internal Medicine and Diplomate, Endocrinology and Metabolism.
Bernice Welles has been Chief Executive Officer at Alquest Therapeutics, Inc. a neurodegenerative drug development company, since June, 2010, and Chief Medical Officer at Enject, Inc., a medical device company, since August 2009.  Prior to that she was Vice President, Development at Diobex, Inc., a venture-backed biotechnology company, for four years.  Dr. Welles has venture capital experience having been Venture Partner at MPM Capital, L.P. for four years and extensive pharmaceutical experience having been Vice President, Product Development and Senior Director and Director, Specialty Therapeutics Unit, Medical Affairs and Clinical Scientist, Medical Affairs at Genentech, Inc. for eight years.
Bernice Welles has been Chief Executive Officer at Alquest Therapeutics, Inc. a neurodegenerative drug development company, since June, 2010, and Chief Medical Officer at Enject, Inc., a medical device company, since August 2009. Prior to that she was Vice President, Development at Diobex, Inc., a venture-backed biotechnology company, for four years.  Dr. Welles has venture capital experience having been Venture Partner at MPM Capital, L.P. for four years and extensive pharmaceutical experience having been Vice President, Product Development and Senior Director and Director, Specialty Therapeutics Unit, Medical Affairs and Clinical Scientist, Medical Affairs at Genentech, Inc. for eight years.

Dr. Welles has a BA in Music from Brandeis University, a MS in Urban and Environmental Policy from Tufts University, a MD from Albany Medical College, and a M.B.A. from The Wharton School of Business, University of Pennsylvania. She has Medical Licensure, State of California, Diplomate, American Board of Internal Medicine and Diplomate, Endocrinology and Metabolism.
Chief Executive Officer, Alquest Therapeutics, Inc. and Chief Medical Officer, Enject, Inc.
Chief Executive Officer, Alquest Therapeutics, Inc. and Chief Medical Officer, Enject, Inc.
Chief Executive Officer, Alquest Therapeutics, Inc. and Chief Medical Officer, Enject, Inc.
Chief Executive Officer, Alquest Therapeutics, Inc. and Chief Medical Officer, Enject, Inc.
J. Gregory Swendsen

President of Swendsen & Company

J. Gregory Swendsen is President of Swendsen & Company, a management company founded in 1984 that specializes in venture capital in the applied technologies. Mr. Swendsen is a founder of SuperGen, Inc. (NASDAQ: SUPG), a leading developer of anti-cancer drugs, a founder of Quark Biotech, and served on the board of AMUR Pharmaceuticals, which he financed prior to its sale to SuperGen. Mr. Swendsen has raised over $250 million for pharmaceutical and biotech companies. He currently sits on the board of Planet Biotech, and KineMed, Inc